Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II perioperative BRAF and MEK inhibition for BRAF-mutated ameloblastoma
MOH_2026-03-25_015732Phase 2Not yet recruiting
- Sponsor
- ד"ר שירלי גרינברג
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib and binimetinib in ameloblastoma (2 arms), sponsored by ד"ר שירלי גרינברג. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on MOH_2026-03-25_015732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-25_015732.